share_log

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $24

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $24

Canaccord Genuity 維持對他和她的生命值的買入,將目標股價上調至 24 美元
Benzinga ·  05/22 22:52

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $20 to $24.

Canaccord Genuity分析師瑪麗亞·裏普斯維持Hims & Hers Hers(紐約證券交易所代碼:HIMS)的買入,並將目標股價從20美元上調至24美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論